Shopping Cart

Remove All

Your shopping cart is currently empty

Proceed to checkout Continue shopping

PI4KIII beta inhibitor 3

Name: PI4KIII beta inhibitor 3
Brand: TargetMol
SKU: T12467
Rating: 4.5 (1 reviews)

Copy Product Info

😃Good

Catalog No. T12467Cas No. 1245319-54-3

PI4KIII beta inhibitor 3 is a novel, highly effective inhibitor of PI4KIIIβ with an IC50 of 5.7 nM.

PI4KIII beta inhibitor 3

Copy Product Info

😃Good

Catalog No. T12467Cas No. 1245319-54-3

PI4KIII beta inhibitor 3 is a novel, highly effective inhibitor of PI4KIIIβ with an IC50 of 5.7 nM.

Pack Size	Price	USA Warehouse	Global Warehouse	Quantity
500 μg	$366	35 days	35 days
1 mg	$696	35 days	35 days

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Resource Download

Product Introduction

Bioactivity

Description	PI4KIII beta inhibitor 3 is a novel, highly effective inhibitor of PI4KIIIβ with an IC50 of 5.7 nM.
Targets&IC50	PI4KIIIβ:5.7 nM
In vitro	PI4KIII beta inhibitor 3 is a potent PI4KIII inhibitor with an IC50 of 5.7 nM. It exhibits significant immunosuppressive activity in the mixed lymphocyte reaction (MLR) assay with an IC50 of 3 nM and inhibits IL2 and IFNγ secretion with IC50 values of less than 1 nM, demonstrating effectiveness comparable to cyclosporine A, whose IC50 values for IFNγ and IL2 release are 2 nM and less than 1 nM, respectively [1].
In vivo	Oral administration of PI4KIII beta inhibitor 3 results in prolonged graft survival in 3 out of 6 grafts in each group at day 30. Several grafts continued beating after withdrawal of the treatment (up to 60 days), indicating the induction of a certain type of graft tolerance. To evaluate the operational tolerance phenotype, animals with functional graft at day 60 are challenged with a second graft from the same donor strain or from a third party.

Chemical Properties

Molecular Weight	446.53
Formula	C₂₂H₂₂N₈OS
Cas No.	1245319-54-3
Smiles	Cc1ccc(NC(=O)N2CCN(CC2)c2nc(N)nc3sc(nc23)-c2cccnc2)cc1
Relative Density.	1.432 g/cm3 (Predicted)

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

DMSO: 20 mg/mL (44.79 mM), Sonication is recommended.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	2.2395 mL	11.1975 mL	22.3949 mL	111.9746 mL
5 mM	0.4479 mL	2.2395 mL	4.4790 mL	22.3949 mL
10 mM	0.2239 mL	1.1197 mL	2.2395 mL	11.1975 mL
20 mM	0.1120 mL	0.5599 mL	1.1197 mL	5.5987 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc